Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Generic Drug, Device Makers Big Beneficiaries Of Beijing’s Healthcare Reforms

This article was originally published in PharmAsia News

Executive Summary

Analysts observe that competitive pharmaceutical companies, especially big ones, will be the first to enjoy China's RBM 850 billion in funding for healthcare reforms. Domestic players, especially those in the medical device sector, will have an edge due to lower costs. However, overseas drug and device makers are likely to change their previous strategy and make inroads into the third-tier market. TCM will be included in the revised essential drug catalog, bringing it unprecedented opportunities. Chain drugstores do not see much benefit for now and are awaiting more specific rules on reform of hospital income from drug sales. Software service providers, such as IBM, see potential in moving into the rural areas. Private health insurance will see the market shrink due to public insurance expansion, but this is expected to spur private insurance outifts to offer more innovative products. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts